The landscape for viral vector upstream processes – PROS and CONS

Viral vector manufacturing market is rising quickly, pushed by the request for safe and high-quality gene and cell therapy carriers. However, a shift in the development, manufacturing and regulation strategy combined with optimization of time and costs is mandatory to fulfill the demand.

In this context, smart selection of cell line and culture strategy can guarantee a high titer stability and purity, reducing the costs of production at large scale.

In this white paper, you will find a focus on:

  • Cell lines and transfection strategy: transient transfected and stable transfected cell lines
  • Bioreactors and culture strategy: adherent cell culture and suspension cell culture
  • Media selection: Serum and serum-free medium


Viral Vectored Gene therapies approved worldwide